Peers of Relmada Therapeutics Inc (RLMD)
Health Care · Pharmaceuticals
Enterprise value divided by EBITDA over the last 12 months. A common way to compare companies with different amounts of debt.
Latest EV/EBITDA
-2.98x
As of Nov 2, 2026
Beyond EV/EBITDA, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | EV/EBITDA |
|---|---|
| Nov 2, 2026 | -2.98x |
| Oct 30, 2026 | -2.52x |
| Oct 29, 2026 | -2.29x |
| Oct 28, 2026 | -2.14x |
| Oct 27, 2026 | -1.91x |
| Oct 26, 2026 | -1.95x |
| Oct 23, 2026 | -2.01x |
| Oct 22, 2026 | -2.05x |
EV/EBITDA = Enterprise Value / EBITDA (TTM). Enterprise Value = Market Cap + Total Debt − (Cash & Short-Term Investments + Long-Term Investments).
EV/EBITDA is widely used because it removes the effects of financing and non-cash accounting items.
Read the general EV/EBITDA definition, formula, and analyst usage guide.
EV/EBITDA guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
